| Literature DB >> 32758449 |
Michael S Breen1, Paras Garg2, Lara Tang3, Danielle Mendonca4, Tess Levy3, Mafalda Barbosa5, Anne B Arnett6, Evangeline Kurtz-Nelson6, Emanuele Agolini7, Agatino Battaglia8, Andreas G Chiocchetti9, Christine M Freitag9, Alicia Garcia-Alcon10, Paola Grammatico11, Irva Hertz-Picciotto12, Yunin Ludena-Rodriguez13, Carmen Moreno10, Antonio Novelli7, Mara Parellada10, Giulia Pascolini11, Flora Tassone14, Dorothy E Grice15, Daniele Di Marino16, Raphael A Bernier6, Alexander Kolevzon4, Andrew J Sharp17, Joseph D Buxbaum18, Paige M Siper19, Silvia De Rubeis20.
Abstract
Helsmoortel-Van der Aa syndrome (HVDAS) is a neurodevelopmental condition associated with intellectual disability/developmental delay, autism spectrum disorder, and multiple medical comorbidities. HVDAS is caused by mutations in activity-dependent neuroprotective protein (ADNP). A recent study identified genome-wide DNA methylation changes in 22 individuals with HVDAS, adding to the group of neurodevelopmental disorders with an epigenetic signature. This methylation signature segregated those with HVDAS into two groups based on the location of the mutations. Here, we conducted an independent study on 24 individuals with HVDAS and replicated the existence of the two mutation-dependent episignatures. To probe whether the two distinct episignatures correlate with clinical outcomes, we used deep behavioral and neurobiological data from two prospective cohorts of individuals with a genetic diagnosis of HVDAS. We found limited phenotypic differences between the two HVDAS-affected groups and no evidence that individuals with more widespread methylation changes are more severely affected. Moreover, in spite of the methylation changes, we observed no profound alterations in the blood transcriptome of individuals with HVDAS. Our data warrant caution in harnessing methylation signatures in HVDAS as a tool for clinical stratification, at least with regard to behavioral phenotypes.Entities:
Keywords: ADNP; DNA methylation; Helsmoortel-Van der Aa syndrome; autism spectrum disorder; biomarkers; epigenetic signature; episignature; genotype-phenotype correlations; intellectual disability; neurodevelopmental disorders
Mesh:
Substances:
Year: 2020 PMID: 32758449 PMCID: PMC7477006 DOI: 10.1016/j.ajhg.2020.07.003
Source DB: PubMed Journal: Am J Hum Genet ISSN: 0002-9297 Impact factor: 11.043